Roquette expands plant-based excipient portfolio with Crest Cellulose acquisition
Crest Cellulose, an Indian excipient manufacturer, has been acquired by plant-based pharmaceutical excipient provider Roquette in a bid to increase the latter’s presence in the Asia Pacific region.
French provider of plant-based ingredients and pharmaceutical/nutraceutical excipients Roquette has announced their complete acquisition of Indian excipient manufacturer Crest Cellulose, expanding their capacity to meet global demand for plant-based excipients.
India’s pharmaceutical industry is one of the largest global providers of generic medicines at a time when the production of generics in the Asia Pacific region is increasing in general. The acquisition of Crest Cellulose is hoped to establish a reinforced presence for Roquette in India and Asia, while also providing a global network of pharmaceutical research, development, and innovation facilities.
Crest Cellulose is set to be smoothly integrated into Roquette’s existing rigorous quality standards, meeting all major international regulatory requirements for excipients produced at the facility. Such plant-based excipients include MICROCEL, a microcrystalline cellulose, and LYCATAB CT, a partially pregelatinized starch.
VP Roquette Pharma Solutions Paul Smaltz commented on the acquisition: “At Roquette, we believe true innovation can only be achieved in an environment where ingredient safety is completely assured... There’s no room for compromise or shortcuts when tackling the world’s greatest health challenges. The team at Crest Cellulose share our conviction that quality is king, always striving to optimize processes and redefine what’s possible in drug delivery. As a global leader in health and nutrition, we’re excited to harness our newly expanded capabilities to support our network of customers and partners in India, Asia, and the rest of the world.
The acquisition will also focus on protecting the health of the planet and sustainable practices, a core pillar of Roquette’s ethos in bringing about healthier futures. Crest Cellulose will become the latest recipient of the Greentech ‘Environmental Protection’ award, recognising the environmental efforts of companies respecting the planet and its natural resources. Smaltz added: “Adding Crest Cellulose to the Roquette family gives us an opportunity to expand the reach of our sustainable development initiatives underpinned by four key pillars – innovating, sourcing, biorefining, acting – to build a healthier tomorrow. For Crest Cellulose and its customers, this means sustainable development will become central to every operation – ensuring we deliver top quality solutions that champion people, the planet, and prosperity. Supporting our commitment to reducing greenhouse gas emissions by 25% between 2021 and 2030, plans are in motion to install an additional 0.5 megawatt solar panel to the 10 kilowatts already in place at the site. This investment is designed to provide renewable energy for decades to come.”
Source: Roquette Complete Acquisition of Crest Cellulose - Corporate Pharma| Roquette
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance